Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 15/20 | 0.38 |
| ▸ | PPARA | Q07869 | 15/20 | 0.38 |
| ▸ | PPARG | P37231 | 12/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625325 | 0.81 | PPARD (0.37) | PPARDPPARAPPARG | |
| SCHEMBL3170727 | 0.79 | CCR2 (0.42) | PPARDPPARA | |
| SCHEMBL3627991 | 0.79 | PPARD (0.35) | PPARDPPARAPPARGKCNH2 | |
| SCHEMBL3165046 | 0.77 | PPARD (0.38) | PPARDPPARAPPARG | |
| SCHEMBL3164000 | 0.73 | CCR2 (0.41) | PPARDPPARA | |
| SCHEMBL13406155 | 0.73 | CCR2 (0.45) | KCNH2 | |
| SCHEMBL14513600 | 0.72 | CCR2 (0.51) | — | |
| SCHEMBL14513598 | 0.71 | CCR2 (0.52) | — | |
| SCHEMBL3160882 | 0.70 | CCR2 (0.39) | PPARDPPARAKCNH2 | |
| SCHEMBL18255085 | 0.69 | P2RX7 (0.41) | PPARDPPARAPPARGHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700591-B2 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK & CO., INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700591-B2 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK & CO., INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700591-B2 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK & CO., INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20060069088-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069088-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | CCR1, CCR2, CCRL2 | PPARD 193/4885PPARA 286/4885PPARG 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.